Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Newly Diagnosed Diffuse Large B-Cell Lymphoma Patients Treated with Immunochemotherapy Who Are Alive and Progression Free 12 Months After Diagnosis Have a Subsequent Overall Survival Similar to That of the General Population

Matthew J Maurer, MS, Herve Ghesquieres, MD, PhD, Thomas E. Witzig, MD, Carrie A. Thompson, MD, Ivana N. Micallef, MD, William R Macon, MD, Sergei I Syrbu, MD, Paul Kurtin, MD, Cristine Allmer, BS, Therese Gargi, Emmanuelle Nicolas-Virelizier, MD, Catherine Sebban, MD, Susan L Slager, PhD, Thomas M Habermann, MD, Brian K Link, MD, James R Cerhan, MD, PhD

Blood (2012) 120 (21): 1540.

https://doi.org/10.1182/blood.V120.21.1540.1540

Published: 2012

Journal Articles

Phase I Trial of Rituximab, Cladribine and Temsirolimus (RCT) for Initial Therapy of Mantle Cell Lymphoma

David J. Inwards, MD, Paul Fishkin, MD, Betsy R. LaPlant, Matthew T. Drake, MD, PhD, Paul Kurtin, MD, Daniel Nikcevich, Donald Wender, MD, Bradley Lair, MD, Thomas E. Witzig, MD

Blood (2012) 120 (21): 3661.

https://doi.org/10.1182/blood.V120.21.3661.3661

Published: 2012

Journal Articles

Primary Parotid MALT Lymphoma: Clinical Characteristics and Treatment – a Single Institution Experience

Jason M. Jones, MD, Thomas M. Habermann, MD, Kay M. Ristow, Paul Kurtin, MD, Ellen McPhail, MD, Carrie A. Thompson, MD, Joseph P. Colgan, MD, Luis F. Porrata, MD, Svetomir N. Markovic, MD, PhD, Thomas E. Witzig, MD, James A. Martenson, Jr., MD, Grzegorz S. Nowakowski, MD

Blood (2011) 118 (21): 1580.

https://doi.org/10.1182/blood.V118.21.1580.1580

Published: 2011

Journal Articles

A Phase II Study of the Farnesyltransferase Inhibitor Tipifarnib Demonstrates Anti-Tumor Activity In Patients with Relapsed and Refractory Lymphomas

Blood (2010) 116 (21): 287.

https://doi.org/10.1182/blood.V116.21.287.287

Published: 2010

Journal Articles

Elevation of Serum Free Light Chains Are Common In Lymphoma and Associated with Poor Event Free and Overall Survival

Matthew J Maurer, James Cerhan, MD, PhD, Jerry A Katzmann, PhD, Brian Link, Ivana N Micallef, MD, Joseph Colgan, MD, Thomas M. Habermann, MD, David James Inwards, MD, Svetomir Markovic, MD, PhD, Stephen M. Ansell, MD, PhD, Luis Porrata, MD, Patrick B Johnston, MD, Grzegorz S. Nowakowski, MD, Carrie A Thompson, MD, Mamta Gupta, Ph.D, Sergei I Syrbu, MD, Paul Kurtin, MD, William Macon, MD, Thomas E. Witzig, MD

Blood (2010) 116 (21): 4136.

https://doi.org/10.1182/blood.V116.21.4136.4136

Published: 2010

Journal Articles

Primary Pulmonary MALT Lymphoma: Clinical Characteristics and Treatment Outcomes – Single Institution Experience

Grzegorz S. Nowakowski, MD, Kay Ristow, Paul Kurtin, MD, Mark S Allen, Ivana N Micallef, MD, Joseph Colgan, David James Inwards, MD, Ellen McPhail, MD, Svetomir Markovic, MD, PhD, Stephen M. Ansell, MD, PhD, Luis Porrata, MD, Patrick B Johnston, MD, PhD, Carrie A Thompson, MD, Thomas E. Witzig, MD, Thomas M. Habermann, MD

Blood (2010) 116 (21): 4168.

https://doi.org/10.1182/blood.V116.21.4168.4168

Published: 2010

Journal Articles

PET Scan Results of NCCTG N0489: Epratuzumab and Rituximab in Combination with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone Chemotherapy (ER-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma.

Ivana N. Micallef, MD, Matthew J. Maurer, Thomas E. Witzig, MD, Daniel Nikcevich, MD, PhD, Paul Kurtin, MD, Michael W. Cannon, MD, Patrick J. Flynn, MD, Gamini S. Soori, MD, Val Lowe, MD, Gregory Wiseman, MD

Blood (2009) 114 (22): 137.

https://doi.org/10.1182/blood.V114.22.137.137

Published: 2009

Journal Articles

A Phase II Study of Temsirolimus (CCI-779) in Combination with Rituximab in Patients with Relapsed or Refractory Mantle Cell Lymphoma.

Stephen M Ansell, Hui Tang, BS, MA, PhD, Paul Kurtin, Patricia Koenig, David J Inwards, Keith Shah, Thomas E Witzig, MD

Blood (2009) 114 (22): 1665.

https://doi.org/10.1182/blood.V114.22.1665.1665

Published: 2009

Journal Articles

The Natural History of Smoldering (Asymptomatic) Multiple Myeloma.

Robert Kyle, MD, Ellen Remstein, MD, Terry Therneau, PhD, Angela Dispenzieri, MD, Paul Kurtin, MD, Janice Hodnefield, Dirk Larson, Matt Plevak, L. Joseph Melton, III, MD, S.Vincent Rajkumar, MD

Blood (2005) 106 (11): 3396.

https://doi.org/10.1182/blood.V106.11.3396.3396

Published: 2005

Journal Articles

Absolute Lymphocyte Count and CD4 Count Predict a Superior Progression-Free Survival in Non-Hodgkin Lymphoma Patients Treated with Rituximab and Interleukin-12.

Cristina Joao, MD, Luis F. Porrata, MD, Thomas Witzig, MD, Paul Kurtin, Ivana Micallef, MD, Svetomir N. Markovic, MD, PhD, Charles Erlichman, MD, Anne Novak, Stephen M. Ansell, MD, PhD

Blood (2005) 106 (11): 1495.

https://doi.org/10.1182/blood.V106.11.1495.1495

Published: 2005

Journal Articles

NFκB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes

Friedrich Feuerhake, Jeffery L. Kutok, Stefano Monti, Wen Chen, Ann S. LaCasce, Giorgio Cattoretti, Paul Kurtin, Geraldine S. Pinkus, Laurence de Leval, Nancy L. Harris, Kerry J. Savage, Donna Neuberg, Thomas M. Habermann, Riccardo Dalla-Favera, Todd R. Golub, Jon C. Aster, Margaret A. Shipp

Blood (2005) 106 (4): 1392–1399.

https://doi.org/10.1182/blood-2004-12-4901

Published: 2005

Includes: Supplemental data

Journal Articles

Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response

Blood (2005) 105 (5): 1851–1861.

https://doi.org/10.1182/blood-2004-07-2947

Published: 2005

Includes: Supplemental data

Journal Articles

Anti-Tumor Activity of Single-Agent CCI-779 for Relapsed Mantle Cell Lymphoma: A Phase II Trial in the North Central Cancer Treatment Group.

Thomas Witzig, M.D., Susan Geyer, Ph.D., Irene Ghobrial, M.D., David Inwards, M.D., Rafael Fonseca, M.D., Scott Kaufmann, M.D., Ph.D., Paul Kurtin, M.D., Joseph Colgan, M.D., William Morice, M.D., Ph.D., Steven Alberts, M.D., Muhammed Salim, M.D., Kendrith Rowland, M.D., Shaker Dakhil, M.D., Roscoe Morton, M.D., Philip Stella, M.D.

Blood (2004) 104 (11): 129.

https://doi.org/10.1182/blood.V104.11.129.129

Published: 2004

Journal Articles

Molecular Profiling of Diffuse Large B-Cell Lymphoma Identifies Robust Subtypes Including One Characterized by Host Inflammatory Response.

Blood (2004) 104 (11): 25.

https://doi.org/10.1182/blood.V104.11.25.25

Published: 2004

Journal Articles

NFκB Activation in Primary Mediastinal Large B-Cell Lymphoma: Nuclear Localization of c-REL and Coordinate Upregulation of NFκB Target Genes.

Friedrich Feuerhake, MD, Jeffery L. Kutok, MD, PhD, Stefano Monti, PhD, Giorgio Cattoretti, MD, Paul Kurtin, MD, Geraldine S. Pinkus, MD, Laurence de Leval, MD, Nancy L. Harris, MD, Kerry J. Savage, MD, Thomas M. Habermann, MD, Riccardo Dalla-Favera, MD, Todd R. Golub, MD, Jon C. Aster, MD, PhD, Margaret A. Shipp, MD, PhD

Blood (2004) 104 (11): 243.

https://doi.org/10.1182/blood.V104.11.243.243

Published: 2004

Journal Articles

The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma

Blood (2003) 102 (12): 3871–3879.

https://doi.org/10.1182/blood-2003-06-1841

Published: 2003

Includes: Supplemental data

NARROW

Newly Diagnosed Diffuse Large B-Cell Lymphoma Patients Treated with Immunochemotherapy Who Are Alive and Progression Free 12 Months After Diagnosis Have a Subsequent Overall Survival Similar to That of the General Population

Phase I Trial of Rituximab, Cladribine and Temsirolimus (RCT) for Initial Therapy of Mantle Cell Lymphoma

Primary Parotid MALT Lymphoma: Clinical Characteristics and Treatment – a Single Institution Experience

A Phase II Study of the Farnesyltransferase Inhibitor Tipifarnib Demonstrates Anti-Tumor Activity In Patients with Relapsed and Refractory Lymphomas

Elevation of Serum Free Light Chains Are Common In Lymphoma and Associated with Poor Event Free and Overall Survival

Primary Pulmonary MALT Lymphoma: Clinical Characteristics and Treatment Outcomes – Single Institution Experience

PET Scan Results of NCCTG N0489: Epratuzumab and Rituximab in Combination with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone Chemotherapy (ER-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma.

A Phase II Study of Temsirolimus (CCI-779) in Combination with Rituximab in Patients with Relapsed or Refractory Mantle Cell Lymphoma.

The Natural History of Smoldering (Asymptomatic) Multiple Myeloma.

Absolute Lymphocyte Count and CD4 Count Predict a Superior Progression-Free Survival in Non-Hodgkin Lymphoma Patients Treated with Rituximab and Interleukin-12.

NFκB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes

Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response

Anti-Tumor Activity of Single-Agent CCI-779 for Relapsed Mantle Cell Lymphoma: A Phase II Trial in the North Central Cancer Treatment Group.

Molecular Profiling of Diffuse Large B-Cell Lymphoma Identifies Robust Subtypes Including One Characterized by Host Inflammatory Response.

NFκB Activation in Primary Mediastinal Large B-Cell Lymphoma: Nuclear Localization of c-REL and Coordinate Upregulation of NFκB Target Genes.

The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only